Private equity investors in China should prioritize discipline on valuations and operational capabilities rather than spend their time worrying about macroeconomic risks, according to David Liu, chairman and founder of DCP Capital.
Liu (pictured) told the Hong Kong Venture Capital & Private Equity Association's Asia forum that there will be a lot of opportunities as China adjusts to slower growth and introduces structural reforms....
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.